Showing 6561-6570 of 7457 results for "".
- One In Two Latina Influencers Favor Complementing Diet and Exercise with Non-Surgical Body Contouringhttps://practicaldermatology.com/news/one-in-two-latina-influencers-favor-complementing-diet-and-exercise-with-non-surgical-body-contouring/2457742/More than 50 percent of Latina Influencers think that non-surgical body contouring works well with diet and exercise, according to an Allergan-sponsored survey. The survey results were part of a panel discussion with Vivian Bucay, MD a San Antonio, Texas dermatologist; Gia Fey, Curveygirl
- Skin Cancer Survey Spotlights Frustration with Perceptions of "Less Serious" Conditionhttps://practicaldermatology.com/news/skin-cancer-survey-spotlights-frustration-with-perceptions-of-less-serious-condition/2457743/People living with skin cancer struggle with perceptions that their condition is less serious than other types of cancer despite significant physical and emotional impact, according to Skin Cancer In America 2018, a national survey by Health Union, LLC of people diagnosed with the condition.
- DermTech: Carcinome Clinical Study Enrollment Completehttps://practicaldermatology.com/news/dermtech-carcinome-clinical-study-enrollment-complete/2457745/DermTech, Inc., the global leader in non-invasive molecular dermatology, announced completion of enrollment in the Carcinome™ clinical study. The goal of the Carcinome™ study is to develop a non-invasive genomic test to differentiate basal cell carcinoma (BCC) and squamous cell
- FDA: Pills Don't Replace Sunscreenhttps://practicaldermatology.com/news/fda-pills-dont-replace-sunscreen/2457749/The U.S. Food and Drug Administration (FDA) is cracking down on companies marketing supplements that claim to counter the effects of the sun's ultraviolet rays. These companies — marketing products called
- Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous Sclerosishttps://practicaldermatology.com/news/rapamycin-lotion-reduces-facial-tumors-caused-by-tuberous/2457750/Rapamycin lotion significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with tuberous sclerosis complex (TSC), researchers from The University of Texas Health Science Center at Houston (UTHealth) report. Findings of the multicenter, international stud
- Skincare on Trial: Revision Introduces New Patient-Friendly Optionhttps://practicaldermatology.com/news/skincare-on-trial-revision-introduces-new-patient-friendly-option/2457752/Revision Skincare has introduced a collection of five comprehensive 45-day trial regimens they say are designed to address the needs of
- EWG: Two-Thirds of Sunscreen Products Offer Poor Protection or Have Worrisome Ingredientshttps://practicaldermatology.com/news/ewg-two-thirds-of-sunscreen-products-offer-poor-protection-or-have-worrisome-ingredients/2457756/The Environmental Working Group (EWG) released its 12th annual Guide to Sunscreens, rating the safety and efficacy of more than 1,000 sunscreens, moisturizers and lip balms that advertise sun protection, and found
- FDA Greenlights Restylane Lyft for Hand Rejuvenationhttps://practicaldermatology.com/news/fda-greenlights-restylane-lyft-for-hand-rejuvenation/2457757/The US Food and Drug Administration has approved Restylane Lyft for use on the dorsal hands of people older than 21, making it the first hyaluronic acid (HA) injectable gel approved for this use. Radiesse (Calcium Hydroxylapatite) is also approved for the correction of lost
- Greater Skin Cancer Risk Seen in U.S. Military Personnelhttps://practicaldermatology.com/news/greater-skin-cancer-risk-seen-in-us-military-personnel/2457762/U.S. military personnel are more likely to develop skin cancer than the general population, according to a review of nine published studies in the Journal of the American Academy of Dermatology (JADD). The f
- FDA Frowns on Evolus' Botox Rivalhttps://practicaldermatology.com/news/fda-frowns-on-evolus-botox-rival/2457763/The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more